Haemonetics Corporation (HAE)

In the past six months, Haemonetics Corp. stock has experienced several notable events and movements. Haemonetics acquired Vivasure Medical Limited for an upfront cash payment of €100 million, aiming to strengthen its position in the large-bore closure market. Analyst ratings and price targets have varied, with firms like Barrington Research, BTIG, and Mizuho maintaining or increasing their positive outlook, while Needham & Company LLC downgraded Haemonetics. Haemonetics reported its quarterly earnings, with $1.27 earnings per share, topping the consensus estimate of $1.12. The stock experienced fluctuations, including a 6.2% drop on January 13, 2026, and a 25.85% increase on November 6, 2025. Over the past six months, the stock has seen a 6.82% increase.

The provided search results do not contain explicit information about the demand seasonality for Haemonetics Corp.'s products and services. However, the company's focus on essential medical markets suggests a relatively stable demand driven by ongoing healthcare needs rather than significant seasonal fluctuations. Product revenue is driven by the demand for disposable blood component collection and processing sets and related equipment. The plasma and hospital segments are emphasized due to their robust growth potential, while the blood center segment faces higher competition.

Haemonetics Corporation is a global healthcare company specializing in medical technology solutions. The company operates within the Health Technology sector, specifically in the Medical Equipment, Supplies & Distribution and Medical Devices industries. Haemonetics' technology addresses various medical markets, including blood and plasma component collection, the surgical suite, and hospital transfusion services. The company's major products and solutions are categorized into three segments: Plasma, Blood Center, and Hospital.

Haemonetics Corporation is a global company with a significant international presence, marketing and selling its products in approximately 95 countries and has offices located in 16 countries. The company's operations and employees are largely concentrated in North America, with a particularly strong plasma market in the U.S. Revenue is derived nearly equally from its three major markets: Asia, Europe, and the Americas. Haemonetics is headquartered in Boston, Massachusetts, USA.

Haemonetics' brand reputation in the past year appears to be generally positive, driven by strategic acquisitions, strong financial performance in key segments, and analyst support. The acquisition of Vivasure Medical Limited was viewed positively, expanding the company's portfolio. Analyst upgrades and increased price targets from firms indicate positive sentiment and support for the stock. Despite overall positive developments, Haemonetics' stock price has seen some declines. Legacy products in cardiology have experienced slower demand due to changing procedure types and increased competition. The company's Q1 FY2026 GAAP revenue fell short of analyst estimates, and adjusted EPS also missed projections.

Haemonetics Corp. has a diverse ownership structure, primarily dominated by institutional investors, who own approximately 89.81% of the company's stock. Public companies and individual investors own approximately 8.81% of the stock, while insiders hold about 1.38%. Major institutional shareholders include BlackRock, Inc., Vanguard Group Inc., Neuberger Berman Group LLC, and State Street Corp.